Product Information

CAS No.	2089288-03-7
Product Name	Azd-1390

Associated Conditions

non-small cell lung carcinoma

* The information provided here is compiled from public sources and is for reference only.

Studies related to this compound and its mechanism of action

Central Nervous System Distribution of the Ataxia-Telangiectasia Mutated Kinase Inhibitor AZD1390: Implications for the Treatment of Brain Tumors.

The Journal of pharmacology and experimental therapeutics • Vol. 383, Issue 1 • 2022

PMID: 36137710 PMC: PMC9513858 DOI: 10.1124/jpet.122.001230

The brain-penetrant ATM inhibitor, AZD1390, promotes axon regeneration and functional recovery in preclinical models of spinal cord injury.

Clinical and translational medicine • Vol. 12, Issue 7 • 2022

PMID: 35818848 PMC: PMC9274214 DOI: 10.1002/ctm2.962

Brain exposure of the ATM inhibitor AZD1390 in humans-a positron emission tomography study.

Neuro-oncology • Vol. 23, Issue 4 • 2021

PMID: 33123736 PMC: PMC8041329 DOI: 10.1093/neuonc/noaa238

The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models.

Science advances • Vol. 4, Issue 6 • 2018

PMID: 29938225 PMC: PMC6010333 DOI: 10.1126/sciadv.aat1719

Azd-1390

CAS No.	2089288-03-7
MDL No.	N/A
MF	C₂₇H₃₂FN₅O₂
MW	477.60
InChI Key	VQSZIPCGAGVRRP-UHFFFAOYSA-N

CUSTOM SYNTHESIS PRECLINICAL SUPPORT

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	2089288-03-7
Product Name	Azd-1390

Associated Conditions

non-small cell lung carcinoma

* The information provided here is compiled from public sources and is for reference only.

Azd-1390

Pricing & Availability

Product Information

Biological Profile

Properties

Associated Conditions

Azd-1390

Pricing & Availability

Product Information

Biological Profile

Properties

Associated Conditions

Documentation

Azd-1390

Pricing & Availability

Product Information

Biological Profile

Properties

Associated Conditions

Related Articles

Central Nervous System Distribution of the Ataxia-Telangiectasia Mutated Kinase Inhibitor AZD1390: Implications for the Treatment of Brain Tumors.

The brain-penetrant ATM inhibitor, AZD1390, promotes axon regeneration and functional recovery in preclinical models of spinal cord injury.

Brain exposure of the ATM inhibitor AZD1390 in humans-a positron emission tomography study.

The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models.

Similar Products

AZD0156

Ktc2hlr3RE

8-Bromo-7-fluoro-1,3-dihydro-3-methyl-1-isopropyl-2H-imidazo[4,5-c]quinolin-2-one

Azd-1390

Pricing & Availability

Product Information

Biological Profile

Properties

Associated Conditions

Related Articles

Central Nervous System Distribution of the Ataxia-Telangiectasia Mutated Kinase Inhibitor AZD1390: Implications for the Treatment of Brain Tumors.

The brain-penetrant ATM inhibitor, AZD1390, promotes axon regeneration and functional recovery in preclinical models of spinal cord injury.

Brain exposure of the ATM inhibitor AZD1390 in humans-a positron emission tomography study.

The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models.

Similar Products

AZD0156

Ktc2hlr3RE

8-Bromo-7-fluoro-1,3-dihydro-3-methyl-1-isopropyl-2H-imidazo[4,5-c]quinolin-2-one

Documentation